Lactobacillus casei and Reduced Duration of Gastrointestinal Adverse Symptom

• Efficacy of proprietary Lactobacillus casei for anti-tuberculosis associated gastrointestinal adverse reactions in adult patients: a randomized, open-label, dose-response trial.

  • 2020-10-07
  • RCT · n = 429
  • Food & Function 11(1)
  • • Song Lin
    • Shanliang Zhao
    • Jiahong Liu
    • Jianwen Zhang
    • Chao Zhang
    • Haibo Hao
    • Yuxia Sun
    • Jing Cai
    • Yang Yang
    • Yan Ma
    • Yuanyuan Li
    • Jinyu Wang
    • A. Ma

  • PubMed: 31815260
  • DOI: 10.1039/c9fo01583c

  11 Insights on

  • Reduced Duration of Gastrointestinal Adverse Symptom

  • High evidence
  • Large Human Trial

  The high and low dose L. casei groups (3.5 d and 5.8 d, respectively) also had shorter duration anti-TB-associated adverse gastrointestinal symptoms than the control group (6.2 d).

  Effect

  Beneficial

  Effect size

  Moderate

  Significant

  Yes

  Dose

  one bottle per day (low-dose group) or two bottles per day (high-dose group), each bottle containing 10 billion CFU